PE20030206A1 - OPHTHALMIC COMPOSITION - Google Patents
OPHTHALMIC COMPOSITIONInfo
- Publication number
- PE20030206A1 PE20030206A1 PE2002000483A PE2002000483A PE20030206A1 PE 20030206 A1 PE20030206 A1 PE 20030206A1 PE 2002000483 A PE2002000483 A PE 2002000483A PE 2002000483 A PE2002000483 A PE 2002000483A PE 20030206 A1 PE20030206 A1 PE 20030206A1
- Authority
- PE
- Peru
- Prior art keywords
- ophthalmic
- mpa
- treatment
- octilphenoxy
- ketotyphene
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Furan Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
QUE COMPRENDE: a)0,005% A 5% DEL PESO TOTAL DE UN FARMACO OFTALMICO SELECCIONADO DE: DICLOFENACO, PREDNISOLONA, CETOTIFENO, ACIDO ASCORBICO, RETINAL, O SALES FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS; b)0,05% A 10% DE UN COMPUESTO DE POLISACARIDO LINEAL COMO HIALURONATO DE SODIO; POR LO MENOS UNO DE LOS SIGUIENTES COMPONENTES: c)AGENTE MEJORADOR DE TONICIDAD; d)REGULADOR DEL pH; e)CONSERVADOR TAL COMO CLORURO DE BENZALCONIO; f)UN PRODUCTO DE REACCION DE ACEITES NATURALES O HIDROGENAODS Y ETILENGLICOL COMO SOLUBILIZANTE, EN PARTICULAR OCTILFENOXI-POLI(ETILENOXI)ETANOL; g)AGENTE FORMADOR DE COMPLEJO; Y/O h) VEHICULO OFTALMICO. DONDE, LA VISCOSIDAD DE LA COMPOSICION ES DE 500 mPa A 2 000 mPa ENTRE 20°C Y 25°C, LA CUAL TIENE APLICACION EN EL TRATAMIENTO DE ENFERMEDADES/DESORDENES OFTALMICOS COMO: GLAUCOMA, MIOSIS, ANESTESIA O INFECCIONES OCASIONADAS POR VIRUS O MICROORGANISMOS; ASI COMO EN LA PREVENCION Y TRATAMIENTO DE CONJUNTIVITIS ALERGICAWHICH INCLUDES: a) 0.005% TO 5% OF THE TOTAL WEIGHT OF A SELECTED OPHTHALMIC DRUG FROM: DICLOFENAC, PREDNISOLONE, KETOTYPHENE, ASCORBIC ACID, RETINAL, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEM; b) 0.05% TO 10% OF A LINEAR POLYSACCHARIDE COMPOUND SUCH AS SODIUM HYALURONATE; AT LEAST ONE OF THE FOLLOWING COMPONENTS: c) TONICITY IMPROVING AGENT; d) pH REGULATOR; e) CONSERVATIVE SUCH AS BENZALCONIUM CHLORIDE; f) A REACTION PRODUCT OF NATURAL OILS OR HYDROGENES AND ETHYLENE GLYCOL AS A SOLUBILIZER, IN PARTICULAR OCTILPHENOXY-POLY (ETHYLENOXY) ETHANOL; g) COMPLEX FORMING AGENT; AND / OR h) OPHTHALMIC VEHICLE. WHERE, THE VISCOSITY OF THE COMPOSITION IS FROM 500 mPa TO 2 000 mPa BETWEEN 20 ° C AND 25 ° C, WHICH IS APPLICABLE IN THE TREATMENT OF OPHTHALMIC DISEASES / DISORDERS SUCH AS: GLAUCOMA, MIOSIS, ANESTHESIA OR INFECTIONS CAUSED BY VIRUSES; AS WELL AS IN THE PREVENTION AND TREATMENT OF ALLERGIC CONJUNCTIVITIS
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01113959 | 2001-06-08 | ||
EP01113958 | 2001-06-08 | ||
EP01115097 | 2001-06-21 | ||
EP01115096 | 2001-06-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20030206A1 true PE20030206A1 (en) | 2003-04-09 |
Family
ID=27440131
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2002000483A PE20030206A1 (en) | 2001-06-08 | 2002-06-07 | OPHTHALMIC COMPOSITION |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1404370A2 (en) |
JP (1) | JP2005508866A (en) |
CN (1) | CN1514735A (en) |
AR (1) | AR034371A1 (en) |
AU (1) | AU2002314149A1 (en) |
BR (1) | BR0210139A (en) |
CA (1) | CA2449213A1 (en) |
PE (1) | PE20030206A1 (en) |
WO (1) | WO2002100437A2 (en) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002345015A1 (en) * | 2001-06-08 | 2002-12-23 | Novartis Pharma Gmbh | Ophthalmic once-a-day composition |
US8580851B2 (en) | 2002-08-21 | 2013-11-12 | Sucampo Ag | Ophthalmic solution |
JP2004143155A (en) * | 2002-10-01 | 2004-05-20 | Taisho Pharmaceut Co Ltd | Ophthalmic solution |
US20040137079A1 (en) * | 2003-01-08 | 2004-07-15 | Cook James N. | Contact lens and eye drop rewetter compositions and methods |
CA2536281C (en) * | 2003-08-21 | 2012-05-15 | Sucampo Ag | Ophthalmic composition comprising a 15-keto-prostaglandin compound |
US20050101582A1 (en) * | 2003-11-12 | 2005-05-12 | Allergan, Inc. | Compositions and methods for treating a posterior segment of an eye |
US20070224278A1 (en) | 2003-11-12 | 2007-09-27 | Lyons Robert T | Low immunogenicity corticosteroid compositions |
AU2005209201B2 (en) | 2004-01-20 | 2010-06-03 | Allergan, Inc. | Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid |
US8119154B2 (en) | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
DE102005035986B4 (en) * | 2005-07-28 | 2009-10-15 | Bausch & Lomb Incorporated | Sterile drippable multiphase emulsifier-free ophthalmic preparation |
US20070077302A1 (en) * | 2005-09-30 | 2007-04-05 | Azaam Alli | Methods for stabilizing ophthalmic compositions |
CN100408046C (en) * | 2005-12-22 | 2008-08-06 | 涂家生 | Macrolide antibiotics sodium hyaluronate eye transfer system |
US7767217B2 (en) * | 2006-03-14 | 2010-08-03 | Foresight Biotherapeutics | Ophthalmic compositions comprising povidone-iodine |
US20090143348A1 (en) * | 2007-11-30 | 2009-06-04 | Ahmet Tezel | Polysaccharide gel compositions and methods for sustained delivery of drugs |
BR112013008186A2 (en) * | 2010-10-04 | 2016-06-21 | Activbiotics Pharma Llc | use of ripazil and analogues to treat eye problems |
KR101412776B1 (en) * | 2013-03-11 | 2014-07-01 | 가톨릭대학교 산학협력단 | Eye drop composition for treating keratoconjunctivitis and preparation method of the same |
US9320709B2 (en) | 2013-08-28 | 2016-04-26 | Presbyopia Therapies Llc | Storage stable compositions and methods for the treatment of refractive errors of the eye |
US9314427B2 (en) | 2013-08-28 | 2016-04-19 | Presbyopia Therapies Llc | Compositions and methods for the improvement of distance vision and the treatment of refractive errors of the eye |
US10064818B2 (en) | 2013-08-28 | 2018-09-04 | Presbyopia Therapies, LLC | Compositions and methods for the treatment of presbyopia |
US9833441B2 (en) | 2013-08-28 | 2017-12-05 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
US9968594B2 (en) | 2013-08-28 | 2018-05-15 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
US9844537B2 (en) | 2013-08-28 | 2017-12-19 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
US9089562B2 (en) | 2013-08-28 | 2015-07-28 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
US10617763B2 (en) | 2013-08-28 | 2020-04-14 | Presbyopia Therapies, LLC | Compositions and methods for the treatment of presbyopia |
US10307408B2 (en) | 2013-08-28 | 2019-06-04 | Presbyopia Therapies, LLC | Contact lens compositions and methods for the treatment of presbyopia |
US11179327B2 (en) | 2013-08-28 | 2021-11-23 | Lenz Therapeutics, Inc. | Compositions and methods for the treatment of presbyopia |
WO2018033792A2 (en) | 2016-08-19 | 2018-02-22 | Orasis Pharmaceuticals Ltd. | Ophthalmic pharmaceutical compositions and uses relating thereto |
US11648247B1 (en) | 2021-12-16 | 2023-05-16 | Lenz Therapeutics, Inc. | Compositions and methods for the treatment of presbyopia |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1229075B (en) * | 1985-04-05 | 1991-07-17 | Fidia Farmaceutici | Topical compsn. contg. hyaluronic acid deriv. as vehicle |
RU2089191C1 (en) * | 1994-01-28 | 1997-09-10 | Научно-производственная фирма "Нарт" | Method of prolongation of physiological effect of thymolol with respect to intraocular pressure decreasing |
CA2193149C (en) * | 1995-12-22 | 2002-04-23 | David H. Donabedian | Cationic therapuetic agents and delivery systems |
JPH1160505A (en) * | 1997-05-20 | 1999-03-02 | Senju Pharmaceut Co Ltd | Antiseptic composition |
DE19923829A1 (en) * | 1999-05-17 | 2000-11-23 | Ulrich Kluegel | Complex of hyaluronate, active ingredient and water, useful as topical pharmaceutical or cosmetic composition, is stable and has high content of active agent |
US6777429B1 (en) * | 1999-07-23 | 2004-08-17 | Novartis Ag | Ophthalmic composition |
-
2002
- 2002-06-06 AR ARP020102106A patent/AR034371A1/en unknown
- 2002-06-07 AU AU2002314149A patent/AU2002314149A1/en not_active Abandoned
- 2002-06-07 BR BR0210139-4A patent/BR0210139A/en not_active Application Discontinuation
- 2002-06-07 CA CA002449213A patent/CA2449213A1/en not_active Abandoned
- 2002-06-07 WO PCT/EP2002/006279 patent/WO2002100437A2/en not_active Application Discontinuation
- 2002-06-07 PE PE2002000483A patent/PE20030206A1/en not_active Application Discontinuation
- 2002-06-07 JP JP2003503256A patent/JP2005508866A/en active Pending
- 2002-06-07 CN CNA028115317A patent/CN1514735A/en active Pending
- 2002-06-07 EP EP02740697A patent/EP1404370A2/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO2002100437A3 (en) | 2003-04-24 |
EP1404370A2 (en) | 2004-04-07 |
AR034371A1 (en) | 2004-02-18 |
CN1514735A (en) | 2004-07-21 |
JP2005508866A (en) | 2005-04-07 |
BR0210139A (en) | 2004-06-08 |
AU2002314149A1 (en) | 2002-12-23 |
WO2002100437A2 (en) | 2002-12-19 |
CA2449213A1 (en) | 2002-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20030206A1 (en) | OPHTHALMIC COMPOSITION | |
WO2021147236A9 (en) | Use of substituted aminopropionate compound in treatment of sars-cov-2 infections | |
TW200700070A (en) | Enhanced bimatoprost ophthalmic solution | |
BRPI0416752A (en) | pharmaceutical composition, use of one or more compounds, method for the prevention or treatment of disorders, compounds, and process for the preparation of a pharmaceutical composition | |
EA200700109A1 (en) | METHODS OF TREATMENT OF OPHTHALMOLOGICAL CONDITIONS (OPTIONS) | |
KR101690817B1 (en) | Ophthalmic composition | |
JPWO2007108541A1 (en) | Ophthalmic composition containing xanthan gum and glucose | |
AR064420A1 (en) | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS THAT INCLUDE AN EFFECTIVE AMOUNT OF ANALOGS OF 6-AMINOIMIDAZO [1,2B] PIRIDAZINAS, USEFUL FOR THE TREATMENT OF GLAUCOMA AND / OR CONTROL THE NORMAL OR ELEVATED INTRAOCULAR PRESSURE (IOP). | |
BR0313790A (en) | Carboxylic acid amide compounds with antagonistic effect mch, medicaments containing these compounds and processes for their preparation | |
CN103068364B (en) | Bimatoprost without preservative and timolol solution | |
AR036044A1 (en) | PYRANOINDAZOL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND ITS USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF GLAUCOMA | |
KR101322527B1 (en) | Eye drop preparation comprising xanthan gum and terpenoid | |
AR032138A1 (en) | DERIVATIVES OF 6-HYDROXY-INDAZOL, AN OPHTHALMIC COMPOSITION, AND THE USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF GLAUCOMA | |
CY1110644T1 (en) | 5,6,7-Trihydroxyheptanoic acid and its analogues for the treatment of ophthalmic diseases related to hypercapillary and angiogenic diseases | |
JP2021107464A (en) | Ophthalmic composition | |
ES2177543T3 (en) | METHOD FOR REDUCING INTRAOCULAR PRESSURE IN THE EYE OF MAMMALS BY ADMINISTRATION OF MUSCARINIC ANTAGONISTS. | |
JP6921757B2 (en) | Ophthalmic composition | |
MX2023011377A (en) | 1,3-substituted cyclobutyl derivatives and uses thereof. | |
JP4718160B2 (en) | Ophthalmic composition | |
PE20030064A1 (en) | PHARMACEUTICAL OPHTHALMIC COMPOSITIONS | |
CO2020009992A2 (en) | Ophthalmic compositions comprising bilastine, a beta-cyclodextrin and at least one gelling agent | |
JP4849288B2 (en) | Eye drops and tear film stabilizer | |
JP2003073303A (en) | Method for maintaining refreshing activity of eye drops | |
JP2005247802A (en) | Eye drops | |
KR960700711A (en) | Medicine for treating or preventing cerebrovascular diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |